Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.64 |
| ▸ | HPGD | P15428 | 7/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2337105 | 0.99 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDHSD17B10HTT | |
| SCHEMBL18902039 | 0.87 | KDM4E (0.70) | ALDH1A1KDM4EHPGDHSD17B10HTT | |
| SCHEMBL18902150 | 0.82 | ALDH1A1 (0.57) | ALDH1A1KDM4EHPGDHSD17B10HTT | |
| SCHEMBL1684499 | 0.81 | KDM4E (0.67) | ALDH1A1KDM4EHPGDHSD17B10HTT | |
| SCHEMBL17745192 | 0.81 | KDM4E (0.67) | ALDH1A1KDM4EHPGDHSD17B10HTT | |
| SCHEMBL16678533 | 0.80 | KDM4E (0.65) | ALDH1A1KDM4EHPGDHSD17B10HTT | |
| SCHEMBL22817528 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL197826 | 0.75 | KMT2A (0.68) | ALDH1A1KDM4EHSD17B10HTTSMN1; SMN2 | |
| Bromide SCHEMBL21996101 | 0.73 | KMT2A (0.66) | ALDH1A1KDM4EHSD17B10HTTSMN1; SMN2 | |
| SCHEMBL1684435 | 0.72 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3111956-B1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3111956-B1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3173414-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Biosciences Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2188271-B1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-3111956-A1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-3111956-A1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2306836-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010002985-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009023402-A2 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | BMI1, CREBBP, BAZ2A | ALDH1A1 2357/4885KDM4E 152/4885HPGD 4501/4885 |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, HCCS | ALDH1A1 961/4885KDM4E 2327/4885HPGD 231/4885 |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, NUDC | ALDH1A1 862/4885KDM4E 3222/4885HPGD 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.